1
|
Yumioka T, Osaki M, Sasaki R, Yamaguchi N, Onuma K, Iwamoto H, Morizane S, Honda M, Takenaka A, Okada F. Lysosome-associated membrane protein 2 (LAMP-2) expression induced by miR-194-5p downregulation contributes to sunitinib resistance in human renal cell carcinoma cells. Oncol Lett 2017; 15:893-900. [PMID: 29399154 PMCID: PMC5772808 DOI: 10.3892/ol.2017.7423] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Accepted: 11/07/2017] [Indexed: 12/31/2022] Open
Abstract
Sunitinib is a tyrosine kinase inhibitor that is used as the primary treatment in metastatic renal cell carcinoma (RCC). The main difficulty associated with its use is the development of drug resistance. In the present study, ACHN cells, a human renal cell carcinoma cell line, were used to establish sunitinib-resistant (SR) cells. Microarray analysis and reverse transcription-quantitative polymerase chain reaction revealed that miR-194-5p expression was significantly decreased in SR-ACHN cells when compared with that observed in ACHN cells (P<0.05). Transfection of miR-194-5p, though not with negative control miR, in SR-ACHN cells could significantly inhibit cell proliferation following sunitinib treatment (2.5–40 µM; P<0.05). Western blotting demonstrated that the expression of lysosome-associated membrane protein-2 (LAMP-2), which attenuates the anti-proliferative effect of sunitinib, was significantly higher in SR-ACHN than in ACHN cells (P<0.01). In addition, LAMP-2 expression was suppressed by miR-194-5p transfection in SR-ACHN cells. These data suggested that miR-194-5p downregulation may be associated with sunitinib resistance via the induction of LAMP-2 expression in human RCC.
Collapse
Affiliation(s)
- Tetsuya Yumioka
- Division of Pathological Biochemistry, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan.,Division of Urology, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan
| | - Mitsuhiko Osaki
- Division of Pathological Biochemistry, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan.,Chromosome Engineering Research Center, Tottori University, Tottori 683-8503, Japan
| | - Ryo Sasaki
- Division of Pathological Biochemistry, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan
| | - Noriya Yamaguchi
- Division of Pathological Biochemistry, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan.,Division of Urology, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan
| | - Kunishige Onuma
- Division of Pathological Biochemistry, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan
| | - Hideto Iwamoto
- Division of Urology, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan
| | - Shuichi Morizane
- Division of Urology, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan
| | - Masashi Honda
- Division of Urology, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan
| | - Atsushi Takenaka
- Division of Urology, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan
| | - Futoshi Okada
- Division of Pathological Biochemistry, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan.,Chromosome Engineering Research Center, Tottori University, Tottori 683-8503, Japan
| |
Collapse
|